Portal de investigação
Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes.
Autores da FMUP
Participantes de fora da FMUP
- Lourenço, IM
- Jordan, G
- Golovaty, I
- Torres, H
- Moin, T
- Buysschaert, M
- Bergman, M
Unidades de investigação
Abstract
Filiações
Filiações não disponíveis
Proyectos asociados
Predictors of readmission and mortality in patients with decompensated heart failure according to glycaemic status
Investigador Principal: João Sérgio de Lima Soares Neves
Estudo Clínico Académico (Glycaemic status) . 2023
Association of Glycemic Variability and Time in Range with Lipid Profile in Type 1 Diabetes
Investigador Principal: João Sérgio de Lima Soares Neves
Estudo Clínico Académico (Glycemic Variability) . 2023
Time in Range and Complications of Diabetes: a Cross-Sectional Analysis of patients with Type 1 Diabetes
Investigador Principal: João Sérgio de Lima Soares Neves
Estudo Clínico Académico (Type 1 Diabetes) . 2023
Evaluation of thyroid function in patients hospitalized for acute heart failure
Investigador Principal: João Sérgio de Lima Soares Neves
Estudo Clínico Académico (Heart failure) . 2021
Predictors Of The Effectiveness Of Insulin Pumps In Patiens With Type 1 Diabetes Mellitus
Investigador Principal: João Sérgio de Lima Soares Neves
Estudo Clínico Académico . 2021
Impacto da pandemia COVID-19 no controlo metabólico de doentes com Diabetes Mellitus Tipo 1
Investigador Principal: João Sérgio de Lima Soares Neves
Estudo Clínico Académico . 2022
Influence of Diabetes on Response to Ultrasound Guided Hydrodistension Treatment of Adhesive Capsulitis: a Retrospective Study
Investigador Principal: João Sérgio de Lima Soares Neves
Estudo Clínico Académico (Hydrodistension ) . 2022
Influence of Cystic Fibrosis-Related Diabetes on the Severity of Cystic Fibrosis Phenotype
Investigador Principal: João Sérgio de Lima Soares Neves
Estudo Clínico Académico . 2022
Citar a publicação
Vale C,Lourenço IM,Jordan G,Golovaty I,Torres H,Moin T,Buysschaert M,Neves JS,Bergman M. Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes. Diabetes Obes. Metab. 2024. IF:5,800. (1).
